SEC Comment Letter for Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Jul 17, 2018
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: July 17, 2018 · CIK: 0001607678 · Accession: 0000000000-18-021941
AI Filing Summary & Sentiment
File numbers found in text: 333-226133
Letter
July 17, 2018 Brian Lian President and Chief Executive Officer Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 Re:Viking Therapeutics, Inc. Registration Statement on Form S-3 Filed on July 11, 2018 File No. 333-226133 Dear Dr. Lian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abigail Jacobs at 202-551-2909 or Erin Jaskot at 202-551-3442 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jeff Hartlin
Show Raw Text
July 17, 2018
Brian Lian
President and Chief Executive Officer
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
Re:Viking Therapeutics, Inc.
Registration Statement on Form S-3
Filed on July 11, 2018
File No. 333-226133
Dear Dr. Lian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abigail Jacobs at 202-551-2909 or Erin Jaskot at 202-551-3442 with any
questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeff Hartlin